K-numberK252190
Device nameDeepBT Detector-Plus
ApplicantAitewan Biomedical Technology, Inc.
Product codeQKB
Device classClass II
Decision dateApr 10, 2026
DecisionSubstantially Equivalent
Regulation892.2050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

DeepBT Detector-Plus is an AI software system that assists trained medical professionals in radiation therapy treatment planning by automatically generating initial contours of brain tumors (brain metastases, meningiomas, and acoustic neuromas) on MRI images. The system accepts both T1-weighted contrast-enhanced and T2-weighted MRI images, outputs results in DICOM format for viewing and editing in treatment planning systems, and requires medical professionals to confirm or modify the contours before clinical use.

Technological characteristics

The primary difference from the predicate device (VBrain) is that DeepBT Detector-Plus can process both single-parametric (T1W+C only) and bi-parametric (T1W+C and T2W) MRI images simultaneously, whereas VBrain supports only single-parametric T1W+C images. Both use deep learning neural networks, operate on Linux, integrate with PACS networks, and target the same three tumor types for adult patients. The bi-parametric capability provides improved tumor boundary identification for certain tumors like cystic lesions.

Test standards cited

IEC 62304:2006/A1:2016 (Medical device software life cycle processes) and ISO 14971:2019 (Risk management for medical devices). Software verification and validation followed FDA's June 14, 2023 guidance on 'Content of Premarket Submissions for Device Software Functions' at the Enhanced Documentation Level.

Substantial equivalence argument

DeepBT Detector-Plus is substantially equivalent to VBrain because both are AI-based software systems for brain tumor contouring in radiation therapy with identical intended clinical use, same tumor types, same patient population (adults), and comparable performance metrics. Although DeepBT supports an additional bi-parametric imaging capability that improves accuracy, both products require physician finalization of contours and do not alter clinical workflow, and the performance data demonstrates that DeepBT's results are comparable to the predicate across multiple evaluation metrics.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →